Illumina, Inc.(ILMN)Earnings, Financials & Key Ratios

ILMN•NASDAQ

$142.58

$21.66B mkt cap·26.2× P/E·Price updated May 6, 2026

SectorHealthcare IndustryDiagnostics & Research Sub-IndustryLife Science Instruments and Sequencing Tools

AboutIllumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.Show more

Revenue$4.34B-0.8%
EBITDA$1.13B+336.7%
Net Income$850M+169.5%
EPS (Diluted)5.45+170.9%
Gross Margin66.69%+1.9%
EBITDA Margin26.14%+338.6%
Operating Margin19.92%+204.5%
Net Margin19.59%+170.0%
ROE33.36%+210.7%
ROIC16.77%+245.4%
Debt/Equity0.94-15.1%
Interest Coverage8.55+179.3%

Analysis→Technical→

ILMN Key Insights

Illumina, Inc. (ILMN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 21.5% free cash flow margin
✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

No significant weaknesses identified

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ILMN Price & Volume

Illumina, Inc. (ILMN) stock price & volume — 10-year historical chart

Loading chart...

ILMN Growth Metrics

Illumina, Inc. (ILMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years6.93%

5 Years6.02%

3 Years-1.82%

TTM1.25%

Profit CAGR

10 Years6.3%

5 Years5.32%

3 Years-

TTM188.39%

EPS CAGR

10 Years5.8%

5 Years4.23%

3 Years-

TTM190.33%

Return on Capital

10 Years3.31%

5 Years-8.68%

3 Years-2.26%

Last Year17.61%

ILMN Recent Earnings

Illumina, Inc. (ILMN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)

Q2 2026Latest

Apr 30, 2026

EPS

$1.15

Est $1.05

+9.5%

Revenue

$1.1B

Est $1.1B

+1.7%

Q1 2026

Feb 5, 2026

EPS

$1.35

Est $1.24

+8.9%

Revenue

$1.2B

Est $1.1B

+3.6%

Q4 2025

Oct 30, 2025

EPS

$1.34

Est $1.17

+14.5%

Revenue

$1.1B

Est $1.1B

+1.6%

Q3 2025

Jul 31, 2025

EPS

$1.19

Est $1.02

+16.7%

Revenue

$1.1B

Est $1.1B

-0.6%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 30, 2026	$1.15vs $1.05+9.5%	$1.1Bvs $1.1B+1.7%
Q1 2026	Feb 5, 2026	$1.35vs $1.24+8.9%	$1.2Bvs $1.1B+3.6%
Q4 2025	Oct 30, 2025	$1.34vs $1.17+14.5%	$1.1Bvs $1.1B+1.6%
Q3 2025	Jul 31, 2025	$1.19vs $1.02+16.7%	$1.1Bvs $1.1B-0.6%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
PACBPacific Biosciences of California, Inc.Direct Competitor	516.17M	1.71	-1.60	-23.19%	-325.8%	-13.95%	1.33
BRKRBruker CorporationDirect Competitor	6.44B	42.30	-282	2.08%	-0.75%	-1.11%	0.81
TMOThermo Fisher Scientific Inc.Direct Competitor	175.76B	472.95	26.66	3.91%	15.18%	13.23%	0.76
DHRDanaher CorporationDirect Competitor	123.8B	174.92	34.71	2.9%	14.89%	7.06%	0.35
AAgilent Technologies, Inc.Direct Competitor	33.31B	117.69	25.75	6.73%	18.26%	18.67%	0.50
BIOBio-Rad Laboratories, Inc.Product Competitor	6.99B	259.02	9.29	0.65%	6.52%	2.4%	0.21
NTRANatera, Inc.Product Competitor	29.58B	215.09	-140.58	56.75%	-14.61%	-24.69%	0.16
EXASExact Sciences CorporationProduct Competitor	20.02B	104.91	-95.37	17.69%	-6.4%	-8.66%	1.05

Compare ILMN vs Peers

Illumina, Inc. (ILMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs PACB

Most directly comparable listed peer for ILMN.

Scale Benchmark

vs TMO

Larger-name benchmark to compare ILMN against a more recognizable public peer.

Peer Set

Compare Top 5

vs PACB, BRKR, TMO, DHR

ILMN Income Statement

Illumina, Inc. (ILMN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'17	Dec'18	Dec'19	Jan'21	Jan'22	Jan'23	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	2.75B	3.33B	3.54B	3.24B	4.53B	4.58B	4.5B	4.37B	4.34B	4.39B
Revenue Growth %	14.74%	21.11%	6.3%	-8.58%	39.73%	1.28%	-1.75%	-2.93%	-0.78%	1.25%
Cost of Goods Sold	926M	1.03B	1.08B	1.04B	1.37B	1.61B	1.76B	1.51B	1.45B	1.44B
COGS % of Revenue	33.65%	30.99%	30.37%	31.99%	30.31%	35.17%	39.08%	34.56%	33.31%	-
Gross Profit	1.83B▲ 0%	2.3B▲ 26.0%	2.47B▲ 7.3%	2.2B▼ 10.7%	3.15B▲ 43.2%	2.97B▼ 5.8%	2.74B▼ 7.7%	2.86B▲ 4.3%	2.89B▲ 1.1%	2.95B▲ 0%
Gross Margin %	66.35%	69.01%	69.63%	68.01%	69.69%	64.83%	60.92%	65.44%	66.69%	67.14%
Gross Profit Growth %	9.6%	25.96%	7.26%	-10.7%	43.17%	-5.77%	-7.67%	4.26%	1.12%	-
Operating Expenses	1.22B	1.42B	1.48B	1.62B	3.28B	7.15B	3.81B	3.69B	2.03B	2.03B
OpEx % of Revenue	44.33%	42.51%	41.83%	50.11%	72.4%	156%	84.66%	84.49%	46.77%	-
Selling, General & Admin	674M	794M	835M	941M	2.09B	1.3B	1.61B	1.09B	1.08B	1.08B
SG&A % of Revenue	24.49%	23.82%	23.57%	29.05%	46.22%	28.29%	35.79%	24.98%	24.85%	-
Research & Development	546M	623M	647M	682M	1.19B	1.32B	1.35B	1.17B	951M	949M
R&D % of Revenue	19.84%	18.69%	18.26%	21.06%	26.18%	28.82%	30.06%	26.74%	21.92%	-
Other Operating Expenses	0	0	0	0	0	4.53B	847M	1.43B	0	0
Operating Income	606M▲ 0%	883M▲ 45.7%	985M▲ 11.6%	580M▼ 41.1%	-123M▼ 121.2%	-4.18B▼ 3297.6%	-1.07B▲ 74.4%	-833M▲ 22.1%	864M▲ 203.7%	919M▲ 0%
Operating Margin %	22.02%	26.49%	27.8%	17.91%	-2.72%	-91.16%	-23.73%	-19.05%	19.92%	20.93%
Operating Income Growth %	3.24%	45.71%	11.55%	-41.12%	-121.21%	-3297.56%	74.42%	22.08%	203.72%	-
EBITDA	762M	1.06B	1.17B	767M	128M	-3.79B	-637M	-479M	1.13B	1.12B
EBITDA Margin %	27.69%	31.86%	33.11%	23.68%	2.83%	-82.57%	-14.14%	-10.96%	26.14%	25.53%
EBITDA Growth %	4.67%	39.37%	10.45%	-34.61%	-83.31%	-3057.03%	83.17%	24.8%	336.74%	674.87%
D&A (Non-Cash Add-back)	156M	179M	188M	187M	251M	394M	432M	354M	270M	202M
EBIT	1.08B	951M	1.17B	905M	945M	-4.31B	-1.04B	-1.08B	864M	919M
Net Interest Income	-18M	-13M	23M	-8M	-61M	-15M	-19M	-54M	-61M	-47M
Interest Income	19M	44M	75M	41M	0	11M	58M	46M	40M	29M
Interest Expense	37M	57M	52M	49M	61M	26M	77M	100M	101M	76M
Other Income/Expense	437M	11M	133M	276M	1.01B	-157M	-48M	-346M	222M	142M
Pretax Income	1.04B▲ 0%	894M▼ 14.3%	1.12B▲ 25.1%	856M▼ 23.4%	884M▲ 3.3%	-4.34B▼ 590.5%	-1.12B▲ 74.2%	-1.18B▼ 5.6%	1.09B▲ 192.1%	1.06B▲ 0%
Pretax Margin %	37.9%	26.82%	31.56%	26.43%	19.53%	-94.59%	-24.8%	-26.97%	25.03%	24.16%
Income Tax	365M	112M	128M	200M	122M	68M	44M	44M	236M	208M
Effective Tax Rate %	35%	12.53%	11.45%	23.36%	13.8%	-1.57%	-3.94%	-3.73%	21.73%	19.6%
Net Income	726M▲ 0%	826M▲ 13.8%	1B▲ 21.3%	656M▼ 34.5%	762M▲ 16.2%	-4.4B▼ 678.0%	-1.16B▲ 73.6%	-1.22B▼ 5.3%	850M▲ 169.5%	853M▲ 0%
Net Margin %	26.38%	24.78%	28.28%	20.25%	16.84%	-96.07%	-25.78%	-27.97%	19.59%	19.43%
Net Income Growth %	56.92%	13.77%	21.31%	-34.53%	16.16%	-677.95%	73.64%	-5.34%	169.5%	188.39%
Net Income (Continuing)	678M	782M	990M	656M	762M	-4.4B	-1.16B	-1.22B	850M	853M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	220M	87M	0	0	0	0	0	0	0	0
EPS (Diluted)	4.91▲ 0%	5.54▲ 12.8%	6.72▲ 21.3%	4.43▼ 34.1%	5.05▲ 14.0%	-28.05▼ 655.4%	-7.35▲ 73.8%	-7.69▼ 4.6%	5.45▲ 170.9%	5.54▲ 0%
EPS Growth %	56.87%	12.83%	21.3%	-34.08%	14%	-655.45%	73.8%	-4.63%	170.87%	190.33%
EPS (Basic)	4.97	5.62	6.82	4.46	5.08	-28.05	-7.35	-7.69	5.48	-
Diluted Shares Outstanding	148M	149M	149M	148M	151M	157M	158M	159M	156M	154M
Basic Shares Outstanding	146M	147M	147M	147M	150M	157M	158M	159M	155M	153M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

ILMN Balance Sheet

Illumina, Inc. (ILMN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'17	Dec'18	Dec'19	Jan'21	Jan'22	Jan'23	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	2.98B	4.49B	4.45B	4.48B	2.71B	3.56B	2.61B	2.75B	3.29B	2.74B
Cash & Short-Term Investments	2.15B	3.51B	3.41B	3.47B	1.34B	2.04B	1.05B	1.22B	1.63B	1.16B
Cash Only	1.23B	1.14B	2.04B	1.81B	1.23B	2.01B	1.05B	1.13B	1.42B	1.09B
Short-Term Investments	920M	2.37B	1.37B	1.66B	107M	26M	6M	93M	215M	66M
Accounts Receivable	411M	514M	573M	487M	664M	688M	752M	751M	854M	738M
Days Sales Outstanding	54.51	56.29	59.03	54.88	53.55	54.78	60.94	62.7	71.86	63.57
Inventory	333M	386M	359M	372M	431M	568M	587M	547M	564M	611M
Days Inventory Outstanding	131.26	136.39	121.78	131.06	114.66	128.61	121.74	132.13	142.46	147.97
Other Current Assets	91M	78M	105M	152M	0	268M	216M	228M	238M	234M
Total Non-Current Assets	2.28B	2.47B	2.87B	3.1B	12.5B	8.69B	7.5B	3.56B	3.35B	3.82B
Property, Plant & Equipment	931M	1.07B	1.44B	1.45B	1.7B	1.74B	1.55B	1.23B	1.13B	1.13B
Fixed Asset Turnover	2.96x	3.10x	2.45x	2.23x	2.67x	2.63x	2.90x	3.54x	3.84x	3.86x
Goodwill	771M	831M	824M	897M	7.11B	3.24B	2.54B	1.11B	1.11B	1.28B
Intangible Assets	175M	185M	145M	142M	3.25B	3.29B	2.99B	295M	210M	430M
Long-Term Investments	266M	260M	283M	418M	213M	211M	196M	227M	0	598M
Other Non-Current Assets	46M	48M	105M	171M	232M	212M	217M	121M	449M	1.2B
Total Assets	5.26B▲ 0%	6.96B▲ 32.4%	7.32B▲ 5.1%	7.58B▲ 3.7%	15.22B▲ 100.6%	12.25B▼ 19.5%	10.11B▼ 17.5%	6.3B▼ 37.7%	6.64B▲ 5.4%	6.56B▲ 0%
Asset Turnover	0.52x	0.48x	0.48x	0.43x	0.30x	0.37x	0.45x	0.69x	0.65x	0.69x
Asset Growth %	22.81%	32.38%	5.13%	3.68%	100.62%	-19.48%	-17.47%	-37.66%	5.41%	14.32%
Total Current Liabilities	746M	1.8B	665M	1.24B	1.09B	2.77B	1.57B	1.55B	1.58B	1.57B
Accounts Payable	160M	184M	149M	192M	332M	293M	245M	221M	240M	218M
Days Payables Outstanding	63.07	65.01	50.54	67.64	88.32	66.34	50.81	53.39	60.62	55.4
Short-Term Debt	10M	1.11B	45M	562M	0	1.25B	0	578M	499M	499M
Deferred Revenue (Current)	130M	175M	167M	186M	234M	245M	252M	260M	270M	751M
Other Current Liabilities	219M	63M	64M	83M	241M	188M	223M	70M	249M	849M
Current Ratio	3.99x	2.49x	6.69x	3.60x	2.48x	1.28x	1.66x	1.78x	2.08x	2.08x
Quick Ratio	3.55x	2.27x	6.15x	3.30x	2.09x	1.08x	1.29x	1.42x	1.72x	1.72x
Cash Conversion Cycle	122.7	127.66	130.27	118.3	79.89	117.05	131.87	141.45	153.7	156.15
Total Non-Current Liabilities	1.67B	1.31B	2.04B	1.65B	3.38B	2.88B	2.8B	2.38B	2.34B	1.97B
Long-Term Debt	1.18B	890M	1.14B	673M	1.7B	1.49B	1.49B	1.49B	1.49B	1.97B
Capital Lease Obligations	0	269M	695M	671M	774M	744M	687M	554M	486M	1.52B
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	360M	359M	160M	259M	915M	649M	620M	272M	360M	892M
Total Liabilities	2.29B	3.05B	2.7B	2.89B	4.48B	5.65B	4.37B	3.93B	3.92B	3.53B
Total Debt	1.19B	2B	1.88B	1.91B	2.54B	3.56B	2.26B	2.62B	2.55B	2.46B
Net Debt	-33M	853M	-161M	96M	1.31B	1.54B	1.21B	1.5B	1.14B	1.38B
Debt / Equity	0.39x	0.51x	0.41x	0.41x	0.24x	0.54x	0.39x	1.10x	0.94x	0.94x
Debt / EBITDA	1.56x	1.88x	1.60x	2.49x	19.84x	-	-	-	2.25x	2.20x
Net Debt / EBITDA	-0.04x	0.80x	-0.14x	0.13x	10.22x	-	-	-	1.00x	1.00x
Interest Coverage	29.19x	16.68x	22.50x	18.47x	15.49x	-165.77x	-13.51x	-10.79x	8.55x	12.09x
Total Equity	3.06B▲ 0%	3.93B▲ 28.3%	4.61B▲ 17.3%	4.69B▲ 1.8%	10.74B▲ 128.8%	6.6B▼ 38.6%	5.75B▼ 12.9%	2.37B▼ 58.7%	2.72B▲ 14.7%	3.03B▲ 0%
Equity Growth %	30.76%	28.33%	17.32%	1.76%	128.8%	-38.56%	-12.94%	-58.69%	14.75%	111.91%
Book Value per Share	20.70	26.39	30.96	31.72	71.13	42.03	36.36	14.92	17.46	19.66
Total Shareholders' Equity	2.84B	3.85B	4.61B	4.69B	10.74B	6.6B	5.75B	2.37B	2.72B	3.03B
Common Stock	2M	2M	2M	2M	2M	2M	2M	2M	2M	0
Retained Earnings	2.26B	3.08B	4.07B	4.72B	5.49B	1.14B	-19M	-1.24B	-392M	0
Treasury Stock	-2.34B	-2.62B	-3.02B	-3.85B	-3.7B	-3.75B	-3.79B	-3.93B	-4.7B	0
Accumulated OCI	-1M	-1M	5M	2M	17M	3M	-1M	22M	-10M	0
Minority Interest	220M	87M	0	0	0	0	0	0	0	0

ILMN Cash Flow Statement

Illumina, Inc. (ILMN) cash flow — operating, investing & free cash flow history

Line item	Dec'17	Dec'18	Dec'19	Jan'21	Jan'22	Jan'23	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	875M	1.14B	1.05B	1.08B	545M	392M	478M	837M	1.08B	1.08B
Operating CF Margin %	31.8%	34.26%	29.66%	33.34%	12.04%	8.55%	10.61%	19.14%	24.87%	-
Operating CF Growth %	27.32%	30.51%	-7.97%	2.76%	-49.54%	-28.07%	21.94%	75.1%	28.91%	190.98%
Net Income	678M	782M	990M	656M	762M	-4.4B	-1.16B	-1.22B	850M	853M
Depreciation & Amortization	156M	179M	188M	187M	251M	394M	432M	354M	270M	65M
Stock-Based Compensation	164M	193M	194M	194M	754M	366M	380M	370M	0	-3M
Deferred Taxes	81M	-18M	11M	117M	-76M	-23M	-33M	-112M	119M	62M
Other Non-Cash Items	-399M	24M	-138M	-147M	-994M	3.85B	950M	1.93B	-7M	587M
Working Capital Changes	195M	-18M	-194M	73M	-152M	204M	-90M	-483M	-153M	-70M
Change in Receivables	-26M	-105M	-58M	89M	-164M	-12M	-40M	-25M	-108M	-203M
Change in Inventory	-33M	-53M	25M	-12M	-58M	-135M	-20M	19M	-17M	1M
Change in Payables	10M	45M	-35M	40M	60M	-38M	-44M	-4M	2M	43M
Cash from Investing	-214M	-1.81B	745M	-554M	-1.07B	-591M	-231M	-178M	-55M	-358M
Capital Expenditures	-312M	-296M	-209M	-189M	-208M	-286M	-195M	-128M	-158M	-157M
CapEx % of Revenue	11.34%	8.88%	5.9%	5.84%	4.6%	6.24%	4.33%	2.93%	3.64%	-
Acquisitions	-52M	-100M	-32M	-98M	-2.44B	-265M	-29M	2M	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	96M	-1.42B	0	-132M	0	0	-1M	0	0	-371M
Cash from Financing	-176M	594M	-897M	-766M	-51M	1B	-1.21B	-570M	-744M	-800M
Debt Issued (Net)	-4M	731M	-550M	0	471M	991M	-1.24B	491M	-5M	-5M
Equity Issued (Net)	-180M	-275M	-265M	-675M	60M	63M	67M	-60M	-698M	-525M
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-251M	-201M	-324M	-736M	0	0	0	-116M	-742M	-542M
Other Financing	8M	138M	-82M	-91M	-582M	-54M	-42M	-1B	-41M	-270M
Net Change in Cash	490M▲ 0%	-81M▼ 116.5%	898M▲ 1208.6%	-232M▼ 125.8%	-578M▼ 149.1%	779M▲ 234.8%	-963M▼ 223.6%	79M▲ 108.2%	291M▲ 268.4%	-24M▲ 0%
Free Cash Flow	563M▲ 0%	846M▲ 50.3%	842M▼ 0.5%	891M▲ 5.8%	337M▼ 62.2%	106M▼ 68.5%	282M▲ 166.0%	709M▲ 151.4%	931M▲ 31.3%	989M▲ 0%
FCF Margin %	20.46%	25.38%	23.77%	27.51%	7.45%	2.31%	6.26%	16.22%	21.46%	22.52%
FCF Growth %	35.38%	50.27%	-0.47%	5.82%	-62.18%	-68.55%	166.04%	151.42%	31.31%	13.81%
FCF per Share	3.80	5.68	5.65	6.02	2.23	0.68	1.78	4.46	5.97	5.97
FCF Conversion (FCF/Net Income)	1.21x	1.38x	1.05x	1.65x	0.72x	-0.09x	-0.41x	-0.68x	1.27x	1.16x
Interest Paid	0	0	0	0	9M	17M	73M	83M	0	0
Taxes Paid	149M	99M	164M	119M	233M	122M	65M	105M	0	0

ILMN Key Ratios

Illumina, Inc. (ILMN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	26.85%	23.61%	23.45%	14.1%	9.87%	-50.8%	-18.81%	-30.13%	33.36%	32.84%
Return on Invested Capital (ROIC)	15.98%	16.95%	16%	9.41%	-1.1%	-31.05%	-10.62%	-11.54%	16.77%	16.77%
Gross Margin	66.35%	69.01%	69.63%	68.01%	69.69%	64.83%	60.92%	65.44%	66.69%	67.14%
Net Margin	26.38%	24.78%	28.28%	20.25%	16.84%	-96.07%	-25.78%	-27.97%	19.59%	19.43%
Debt / Equity	0.39x	0.51x	0.41x	0.41x	0.24x	0.54x	0.39x	1.10x	0.94x	0.94x
Interest Coverage	29.19x	16.68x	22.50x	18.47x	15.49x	-165.77x	-13.51x	-10.79x	8.55x	12.09x
FCF Conversion	1.21x	1.38x	1.05x	1.65x	0.72x	-0.09x	-0.41x	-0.68x	1.27x	1.16x
Revenue Growth	14.74%	21.11%	6.3%	-8.58%	39.73%	1.28%	-1.75%	-2.93%	-0.78%	1.25%

ILMN SEC Filings & Documents

Illumina, Inc. (ILMN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 30, 2026·SEC

Material company update

Apr 2, 2026·SEC

Material company update

Feb 5, 2026·SEC

10-K Annual Reports

FY 2026

Feb 12, 2026·SEC

FY 2025

Feb 12, 2025·SEC

10-Q Quarterly Reports

FY 2025

Oct 31, 2025·SEC

FY 2025

Aug 1, 2025·SEC

FY 2025

May 9, 2025·SEC

ILMN Frequently Asked Questions

Illumina, Inc. (ILMN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Illumina, Inc. (ILMN) reported $4.39B in revenue for fiscal year 2025. This represents a 926220% increase from $0.5M in 1999.

Illumina, Inc. (ILMN) saw revenue decline by 0.8% over the past year.

Yes, Illumina, Inc. (ILMN) is profitable, generating $853.0M in net income for fiscal year 2025 (19.6% net margin).

Dividend & Returns

Illumina, Inc. (ILMN) has a return on equity (ROE) of 33.4%. This is excellent, indicating efficient use of shareholder capital.

Illumina, Inc. (ILMN) generated $989.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More ILMN

Illumina, Inc. (ILMN) financial analysis — history, returns, DCA and operating performance tools

Full ILMN Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Illumina, Inc.(ILMN)Earnings, Financials & Key Ratios

ILMN Key Insights

✓Strengths

✗Weaknesses

ILMN Price & Volume

ILMN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

ILMN Recent Earnings

ILMN Peer Comparison

Compare ILMN vs Peers

vs PACB

vs TMO

Compare Top 5

ILMN Income Statement

ILMN Balance Sheet

ILMN Cash Flow Statement

ILMN Key Ratios

ILMN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

ILMN Frequently Asked Questions

Explore More ILMN

Full ILMN Stock Analysis

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation